(Q47594626)

4 February 2018

title

Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes (English)

1 reference

4 February 2018

0 references

1

1 reference

4 February 2018

author name string

Klittich WS

2

1 reference

4 February 2018

Raggio G

3

1 reference

4 February 2018

Kavanagh PL

4

1 reference

4 February 2018

O'Brien JA

5

1 reference

4 February 2018

Shomphe LA

6

1 reference

4 February 2018

Flegel KM

7

1 reference

4 February 2018

Copley-Merriman C

8

1 reference

4 February 2018

Sigler C

9

1 reference

4 February 2018

publication date

1 January 2000

1 reference

4 February 2018

published in

Clinical Therapeutics

1 reference

4 February 2018

volume

22

1 reference

4 February 2018

issue

1

1 reference

4 February 2018

page(s)

116-127

1 reference

4 February 2018

The medical management of hyperglycemia over a 10-year period in people with diabetes.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

Long-term complications of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

Implications of the Diabetes Control and Complications Trial. American Diabetes Association

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

Direct medical costs of complications resulting from type 2 diabetes in the U.S.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

Model of complications of NIDDM. I. Model construction and assumptions.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

Risk factors for diabetic retinopathy: a population-based study in Rochester, Minnesota

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

Glycemic control and cardiopulmonary function in patients with insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

Nursing home residents: a multivariate analysis of their medical, behavioral, psychosocial, and service use characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

A cost analysis of alprostadil in liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987983-7

7 January 2021

10.1016/S0149-2918(00)87983-7

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018